Although cancer cell lines in culture are imperfect models of human tumors, they tend to remain addicted to the factors that initiated tumor formation and hence are well-validated tools for studying precision medicine-based target therapies.31 Therefore, our study suggest that PKCι is an ideal therapeutic target for a subset of ovarian cancer with PRKCI amplification and has laid a foundation on using EpCAM aptamer-delivered PKCι siRNA to treat this subset of ovarian cancer. Here, PRKCI is linked to ovarian cancer.